Completed PHASE2 INTERVENTIONAL 2-arm NCT04649021

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study

Sponsor: BioNTech SE

Conditions SARS-CoV-2

Interventions BNT162b2 Placebo

Updated 8 times since 2021 Last updated: May 9, 2022 Started: Dec 4, 2020 Primary completion: Feb 7, 2021 Completion: Jan 9, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04649021, this PHASE2 trial focuses on SARS-CoV-2 and remains completed. Sponsored by BioNTech SE, it has been updated 8 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
May 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE2

▶ Show 3 earlier versions

Mar 2021 — Apr 2022 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jiangsu, China